I

Isu Abxis Co Ltd
KOSDAQ:086890

Watchlist Manager
Isu Abxis Co Ltd
KOSDAQ:086890
Watchlist
Price: 4 980 KRW -1.39% Market Closed
Market Cap: 178.8B KRW
Have any thoughts about
Isu Abxis Co Ltd?
Write Note
Isu Abxis Co Ltd
/
Balance Sheet
/
Total Receivables

Isu Abxis Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Isu Abxis Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
I
Isu Abxis Co Ltd
KOSDAQ:086890
Total Receivables
₩27.2B
CAGR 3-Years
56%
CAGR 5-Years
42%
CAGR 10-Years
28%
Celltrion Inc
KRX:068270
Total Receivables
₩975.7B
CAGR 3-Years
-10%
CAGR 5-Years
3%
CAGR 10-Years
8%
SK Bioscience Co Ltd
KRX:302440
Total Receivables
₩22.3B
CAGR 3-Years
-25%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Total Receivables
₩46.4B
CAGR 3-Years
18%
CAGR 5-Years
3%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Total Receivables
₩53.9B
CAGR 3-Years
23%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Total Receivables
₩11.2B
CAGR 3-Years
35%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Isu Abxis Co Ltd
Glance View

Market Cap
177.6B KRW
Industry
Biotechnology

ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.

Intrinsic Value
8 552.29 KRW
Undervaluation 42%
Intrinsic Value
Price
I
What is Intrinsic Value?

See Also

What is Isu Abxis Co Ltd's Total Receivables?
Total Receivables
27.2B KRW

Based on the financial report for Jun 30, 2024, Isu Abxis Co Ltd's Total Receivables amounts to 27.2B KRW.

What is Isu Abxis Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
28%

Over the last year, the Total Receivables growth was 42%. The average annual Total Receivables growth rates for Isu Abxis Co Ltd have been 56% over the past three years , 42% over the past five years , and 28% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.